Effects of interferon-alpha on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C

Related Experiment Video

Updated: Oct 26, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

G P Pageaux1, Y le Bricquir, F Berthou

  • 1Service d'Hépatogastroentérologie, Hôpital Saint-Eloi, Montpellier, France.

European Journal of Gastroenterology & Hepatology
|December 17, 1998
PubMed
Abstract

Insights

Interferon-alpha treatment for chronic hepatitis C does not significantly affect drug metabolism by cytochrome P-450 1A2 and 3A enzymes. This suggests co-administration with drugs metabolized by these pathways is safe.

Area of Science:

  • Pharmacology
  • Hepatology
  • Drug Metabolism

Background:

  • Adverse drug interactions with interferon-alpha are not well understood.
  • Interferon-alpha is used to treat chronic hepatitis C.
  • Cytochrome P-450 1A2 and 3A are key enzymes in drug metabolism.

Purpose of the Study:

  • To assess if interferon-alpha impacts drug metabolism.
  • To investigate effects on cytochrome P-450 1A2 and 3A activity.
  • To evaluate drug interaction risks in chronic hepatitis C patients.

Main Methods:

  • Studied 18 chronic hepatitis C patients receiving interferon-alpha.
  • Assessed cytochrome P-450 1A2 activity via in vivo caffeine metabolism.
  • Measured cytochrome P-450 3A activity through cortisol metabolism to 6-beta-hydroxycortisol.

Main Results:

  • No significant changes in caffeine metabolism (CYP 1A2 activity) were observed.
  • No significant alterations in the 6-beta-hydroxycortisol/free cortisol ratio (CYP 3A activity) were found.
  • Interferon-alpha therapy did not alter the activity of these key drug-metabolizing enzymes.

Conclusions:

  • Therapeutic doses of interferon-alpha do not inhibit CYP 1A2 or CYP 3A activity in vivo.
  • Patients with chronic hepatitis C can likely use drugs metabolized by these enzymes alongside interferon-alpha.
  • The risk of significant drug interactions appears low when co-administering interferon-alpha with CYP 1A2 or CYP 3A substrates.

More Related Videos

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...